Scarica l'app Stockscreener
806.53
0.39%
-2.4327
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$808.96
Aprire:
$806.93
Volume 24 ore:
1.13M
Relative Volume:
0.25
Capitalizzazione di mercato:
$763.45B
Reddito:
$53.26B
Utile/perdita netta:
$13.80B
Rapporto P/E:
53.48
EPS:
15.0808
Flusso di cassa netto:
$-50.20M
1 W Prestazione:
-0.81%
1M Prestazione:
+7.16%
6M Prestazione:
-1.49%
1 anno Prestazione:
-11.07%
Intervallo 1D:
$803.23
$812.99
Intervallo di 1 settimana:
$783.85
$834.70
Portata 52W:
$623.78
$935.62
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
806.63 | 725.20B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
192.41 | 466.54B | 92.15B | 25.12B | 18.18B | 10.36 |
|
ABBV
Abbvie Inc
|
231.40 | 409.95B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
131.06 | 255.13B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.26 | 215.61B | 63.43B | 16.42B | 14.72B | 6.4861 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly’s New Asthma Treatment Study: What Investors Need to Know - TipRanks
Eli Lilly Vs Novo Nordisk: One To Walk Away From And One To Run Away From (NYSE:LLY) - Seeking Alpha
Bank of America Securities Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100 - 富途牛牛
Eli Lilly & Co: Strategic Positioning and Clinical Advancements Drive Buy Rating - TipRanks
What Eli Lilly (LLY)'s Drug Pricing Pressure Means for the Future of Its Obesity Franchise - simplywall.st
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk? - AOL.com
Eli Lilly doubles Seaport footprint with new lease, taking entire building at 645 Summer St - The Business Journals
Coinbase CEO’s Longevity Startup Raises $45M From Eli Lilly & Others - Athletech News
Can Eli Lilly and Company (Common Stock) (LLY0) stock survive global slowdown2025 Technical Overview & Community Consensus Trade Alerts - nchmf.gov.vn
Eli Lilly Q3 earnings eyed for insights into drug pricing policies - Proactive financial news
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating - 富途牛牛
Eli Lilly stock price target raised to $930 by BMO on incretin growth - Investing.com
Rumors of Eli Lilly buyout sends Nektar’s shares spiking - PharmaLive
Eli Lilly Corp. buy BMO Capital Markets - sharewise.com
Weight Loss Drugs Market Set to Reach USD 50.26 Billion by 2032, Driven by Prescription Drug Adoption and Breakthrough Formulations – SNS Insider - GlobeNewswire Inc.
Rumors of Eli Lilly Buyout Send Nektar’s Shares Spiking - BioSpace
BMO Capital Adjusts Price Target on Eli Lilly to $930 From $840, Maintains Outperform Rating - MarketScreener
Eli Lilly reports positive Phase 3 results for orforglipron in type 2 diabetes trials - Express Pharma
Anti-aging biotech NewLimit brings in Eli Lilly as investor, raising $45M - Endpoints News
J.L. Bainbridge Buys $45 Million in Eli Lilly Stock Despite Price-Pressure Fears - The Motley Fool
Why Eli Lilly and Company stock remains on buy lists2025 Key Highlights & Trade Opportunity Analysis - nchmf.gov.vn
Can Eli Lilly and Company stock surprise with quarterly resultsTrade Volume Report & Weekly High Return Stock Forecasts - nchmf.gov.vn
Can Eli Lilly and Company (LLY) stock reach $200 price targetNew Guidance & Target Return Focused Stock Picks - nchmf.gov.vn
Major Stock Moves: Eli Lilly, Delta, Caterpillar, Dell, CoreWeave - TipRanks
Can Eli Lilly and Company stock withstand economic slowdownJuly 2025 Levels & Fast Entry and Exit Trade Plans - nchmf.gov.vn
3 Price Catalysts For Eli Lilly (NYSE:LLY) - Seeking Alpha
Eli Lilly (LLY) Reports Positive Results from Breast Cancer Trial - TipRanks
Stock Movers: Oracle, American Express, Eli Lilly - Bloomberg.com
Why Eli Lilly (LLY) Stock Is Down Today - Yahoo Finance
Eli Lilly (LLY) Shares Drop Due to Recent Voucher Snub and Compe - GuruFocus
Eli Lilly falls on orforglipron FDA voucher exclusion, Trump on weight-loss meds - Seeking Alpha
Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks - MSN
Eli Lilly Shares Are Trading Lower Friday: What's Going On? - Benzinga
Novo, Lilly Fall as Trump Touts ‘Much Lower’ Ozempic Price - Bloomberg.com
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs? - Benzinga
Market Jitters: Dow Dips Amid Bank Fears While Eli Lilly and Novo Nordisk Tumble on Trump's Drug Pricing Comments - FinancialContent
Eli Lilly and Company Stock (LLY) Opinions on Drug Pricing Initiative - Quiver Quantitative
Novo, Lilly Shares Drop as Trump Promises $150 Ozempic - BioSpace
Trump says Ozempic will get cheaper. Novo Nordisk, Eli Lilly stock slump - Yahoo Finance
Lilly CSO defends hiring of ex-FDA chief Peter Marks - statnews.com
Eli Lilly, Novo Nordisk Tumbles After Trump Says Weight-Loss Drugs Are 'Too Expensive' - Yahoo Finance
Novo Nordisk, Eli Lilly shares drop as Trump promises lower weight loss drug prices - Proactive financial news
Eli Lilly (LLY) Reports Promising Results from Phase 3 monarchE Trial - GuruFocus
Eli Lilly Sets Ambitious Sustainability Goals Despite Headwinds - Investor's Business Daily
Cantor Fitzgerald maintains Eli Lilly stock rating despite orforglipron setback - Investing.com
Novo Nordisk, Eli Lilly shares drop as Trump vows weight-loss drug price cuts - Yahoo
Eli Lilly Says Verzenio Reduced Risk of Death In Late-Stage Trial In Some Breast Cancer Patients - Stocktwits
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics - sharewise.com
Eli Lilly reports results from Phase 3 monarchE trial - TipRanks
Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug - Investor's Business Daily
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.72%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):